ProCE Banner Activity

Why Long-Acting ART is the Latest Game Changer for HIV Treatment

Clinical Thought
Here are my thoughts on how the emergence of long-acting ART reflects the continued evolution of HIV treatment to better meet the broad needs of our patients and what ongoing research efforts may bring about for future long-acting ART options.

Released: November 30, 2021

Share

Faculty

Jean-Michel Molina

Jean-Michel Molina, MD, PhD

Head of the Department of Infectious Diseases
Saint-Louis Hospital, Assistance-Publique Hôpitaux de Paris
Paris, France
Professor of Infectious Diseases
University of Paris
Paris, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Jean-Michel Molina, MD, PhD

Head of the Department of Infectious Diseases
Saint-Louis Hospital, Assistance-Publique Hôpitaux de Paris
Paris, France
Professor of Infectious Diseases
University of Paris
Paris, France

Jean-Michel Molina, MD, PhD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Merck, and ViiV Healthcare and funds for research support from Gilead Sciences.